Proton Pump Inhibitor Lawsuit Timeline: How MDL 2789 Became a Five-Figure Docket

2016: kidney studies change the public conversation

The federal chronology makes more sense when it begins with the evidence rather than the lawsuit count. In February 2016, researchers analyzing the ARIC cohort and a separate Geisinger replication cohort reported an association between proton pump inhibitor use and incident chronic kidney disease. Later that year, a Veterans Affairs database study comparing new PPI users with new H2-blocker users reported associations with incident CKD, progression, and end-stage renal disease. Both studies were large and clinically important. Neither randomly assigned people to long-term treatment, so differences in illness, prescribing, duration, other medicines, and measured or unmeasured risk factors remained possible explanations for part of the observed pattern.

Those limitations do not make the findings meaningless. They define what the findings can support. Population studies can identify a signal, estimate an association in the studied data, and motivate further research or warning review. They cannot reconstruct why one person's renal function changed. Acute interstitial nephritis, chronic kidney disease, and end-stage kidney disease also are not interchangeable diagnoses. Any litigation timeline that jumps from a 2016 hazard estimate to 'PPIs caused kidney failure' has removed the very uncertainty the researchers and courts must evaluate.

2017: the JPML creates MDL 2789

On August 2, 2017, the Judicial Panel on Multidistrict Litigation transferred 161 federal actions to the District of New Jersey. The panel described overlapping allegations involving products including Nexium, Prilosec, Prevacid, and Protonix and alleged injuries such as acute interstitial nephritis, chronic kidney disease, renal failure, and related conditions. It found that coordinated discovery and pretrial rulings would promote efficiency. That transfer order did not create a class, certify a common injury, or find any warning inadequate.

The distinction matters because several manufacturers and products sit within the PPI category. A pharmacy record may identify a brand, a generic manufacturer, a dose, and a dispensing period that memory alone cannot. Governing state law, prescriber knowledge, diagnosis, latency, and alternative renal risks can differ even when two complaints share an MDL caption. MDL 2789 is therefore a common pretrial workspace for individual actions, not one lawsuit in which every plaintiff rises or falls together.

2020-2022: labeling and bellwether planning move forward

In November 2020, FDA approved revised Protonix materials after identifying new safety information concerning acute or chronic interstitial nephritis that could lead to renal inflammation and reduced function. Current Protonix labeling warns that acute tubulointerstitial nephritis has been observed in patients taking PPIs and may occur at any point during therapy. A regulatory warning tells clinicians and patients about an identified risk and appropriate evaluation. It is not a judgment that a particular manufacturer is legally liable for a particular patient's CKD.

On January 20, 2022, the New Jersey court entered Case Management Order 68. It identified three anticipated bellwether cases and a sequence for trial preparation, subject to later rulings and changes. Bellwethers are selected individual cases used to test recurring evidence and legal theories. Selection is not an endorsement of the plaintiff's case, and an anticipated trial is not a completed outcome. Readers should check the court's current repository before repeating any old calendar date as current.

2026: a large inventory, not a public compensation program

JPML's July 1, 2026 report listed 11,321 actions pending in MDL 2789 and 18,706 actions historically associated with it. 'Pending' is a procedural status on the report date. 'Historical' is cumulative and includes cases that may have left the docket through multiple routes. Neither number identifies how many plaintiffs have complete exposure records, a particular diagnosis, a surviving legal theory, or a favorable resolution. Dividing an imagined fund by either count would manufacture an average that no court source provides.

The monthly report should be paired with signed orders on the District of New Jersey's MDL page. Counts can change when actions are filed, transferred, dismissed, remanded, or otherwise terminated, while a case-management order can change a deadline or sequence. As of the stated verification date, the primary sources reviewed do not announce a universal PPI payment grid, courtwide claim form, or guaranteed eligibility list. A mature docket can still contain sharply individualized disputes.

How to build a timeline that is actually useful

For a reader, the most useful timeline is personal and document-led: the exact medicine and manufacturer; prescription and pharmacy dates; dose changes; reason for treatment; baseline creatinine and estimated glomerular filtration rate; later laboratory trends; nephrology visits; biopsy findings, if any; and other renal risks such as diabetes, hypertension, dehydration, infection, or nephrotoxic medicines. Those records do not predetermine causation. They prevent the analysis from collapsing into 'PPI use plus kidney disease equals proof.'

Medication decisions belong with the prescribing clinician. A person should not stop or switch a PPI because a lawsuit page describes a court event. Legal timing likewise depends on jurisdiction and case-specific facts, not on a generic online countdown. The defensible takeaway from this chronology is narrower: studies reported renal associations, FDA labeling recognizes acute tubulointerstitial nephritis, thousands of federal actions remain coordinated, and individual causation and liability are still questions of proof.

Reader questions

Frequently asked questions